No Data
No Data
Dizal (Jiangsu) Pharmaceutical's Lung Cancer Drug Designated Breakthrough Therapy by NMPA
Dezhi Pharmaceutical (688192.SH) pharmaceutical product obtains breakthrough therapy designation.
Dizhi Pharmaceutical (688192.SH) announced that recently, the National Medical Products Administration Drug Evaluation Center (referred to as "C...
Express News | Sunvozertinib Granted Breakthrough Therapy Designation by China Cde for the First-Line Treatment of Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations
Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
DiZe Pharmaceutical Shuwozhe won the 'breakthrough therapy designation' grand slam in China and the United States, treating EGFR exon20ins non-small cell lung cancer across the board.
Shuozhe is the first and only drug to receive the breakthrough therapy designation for epidermal growth factor receptor (EGFR) exon20 insertion mutation non-small cell lung cancer (NSCLC) in both China and the United States. Shanghai, October 13, 2024 / PRNewswire/ -- Dezhi Medicine (stock code: 688192.SH) announced that the National Medical Products Administration's Center for Drug Evaluation (CDE) has granted breakthrough therapy designation to the company's first independently developed novel lung cancer targeted drug, Shuozhe (generic name: Shuoweitinib tablets).
Dizhil Pharmaceutical (688192.SH): Shuwozhe first-line treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutation obtained breakthrough therapy designation from CDE.
Gelonghui October 13th | Dize Pharmaceutical (688192.SH) announced that the State Drug Administration Drug Evaluation Center (referred to as "CDE") has granted the company its first independently developed new lung cancer targeted drug Shuwozhe (generic name: Shuwotinib tablets) Breakthrough Therapy Designation (BTD), used for locally advanced or metastatic non-small cell lung cancer carrying the epidermal growth factor receptor (EGFR) exon 20 insertion mutation (Exon20ins) who have not received systemic treatment.
No Data
No Data